• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$14.59 -$0.04 (-0.27%)

REAL-TIME: Last trade at

WuXi PharmaTech (Cayman), Inc....

NYSE:WX

WuXi PharmaTech rises 11.6%

WuXi PharmaTech Q1 Results Top View; Backs 2012 Outlook

WuXi PharmaTech (WX) Tops Q1 EPS by 1c; Guides Q2 Sales

WuXi PharmaTech reports Q1 EPS 33c, consensus 27c

WuXi PharmaTech Announces First-Quarter 2012 Results

WuXi PharmaTech Files 2011 Annual Report on Form 20-F

WuXi PharmaTech Files 2011 Annual Report on Form 20-F

WuXi PharmaTech Schedules First-Quarter 2012 Earnings Release

WuXi PharmaTech Schedules First-Quarter 2012 Earnings Release

Jefferies Reiterates a 'Buy' on WuXi PharmaTech (WX); Demand As Good As Ever

Manufacturing Services Boost Growth and Support Earnings During WuXi's Fourth Quarter

WuXi PharmaTech (WX) Tops Q4 EPS by 10c; Guides Q1, FY12 Revs

WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2011 Results, Share Repurchase Program

WuXi PharmaTech Announces Purchase Of Ordinary Shares From General Atlantic

WuXi PharmaTech announces purchase of ordinary shares from General Atlantic

WuXi PharmaTech Announces Purchase of Ordinary Shares from General Atlantic

WuXi PharmaTech Schedules Fourth-Quarter 2011 Earnings Release

Wells Fargo Downgrades WuXi PharmaTech (WX) to Market Perform; Valuation Call - Questioning Acquisition Target

WuXi PharmaTech downgraded to Market Perform from Outperform at Wells Fargo

The Week In Review: Are WuXi PharmaTech And ShangPharma Takeover Targets?

Manning & Napier reports 6.74% passive stake in WuXi PharmaTech

The Long-Term Play In Lab Work (BBH, CRL, ICLR, PRXL, WX)

CROs Will Return to Relevance in 2012

WuXi PharmaTech sees 2011 revenue exceeding top-end of $402M-$406M view

WuXi PharmaTech Provides Update of 2011 Financial Guidance, to Present at J.P. Morgan Healthcare Conference

WuXi PharmaTech Provides Update of 2011 Financial Guidance, to Present at J.P. Morgan Healthcare Conference

Stocks That Are Cheaper Than Julian Robertson Bought

JP Morgan's life science tools and diagnostics analyst holds a conference call

Stocks That Julian Robertson Keeps Buying

Covidien Spins Off Drug Company: 5 Drug Makers Hedge Funds Want Most

WuXi PharmaTech Presents the 2011 Life Science and Chemistry Awards

WuXi PharmaTech Presents the 2011 Life Science and Chemistry Awards

China Biotech Week In Review: WuXi PharmaTech Forms Venture Fund

Tiber Management's Julian Robertson Buys LBTYA, NFLX, WX, GS, GOOG, CVC, Sells AMZN, AAPL, MA, V

WuXi PharmaTech Co., Ltd. to Form $50 Million Venture Fund

Jefferies Cuts Price Targets on WuXi PharmaTech (WX), Outlook Remains Strong Following Acquisitions

WuXi PharmaTech downgraded to Outperform from Buy at CLSA

WuXi PharmaTech - Issues in-line guidance for FY11..

WuXi PharmaTech Q3 Profit Drops; Guides 2011 Revenue In Line

WuXi PharmaTech Announces Third-Quarter 2011 Results

See More Articles...